Medicine Development Needs Radical Reform: Commentary
Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 4
Abstract
Medicines are a vital and an expensive component of health care. The present situation with regard both to the development and licensing of medicines, and to their pricing and supply are in a state that damages the provision of healthcare particularly in poorer countries but also throughout the world. There is surprisingly widespread agreement that the whole process requires radical reform. The political will to bring this about has, however, so far not been sufficient to effect more than rather minor changes
Authors and Affiliations
Peter J. Lachmann
Keywords
Related Articles
- EP ID EP386724
- DOI 10.4172/2167-0870.1000320
- Views 45
- Downloads 0
Hierarchical Agglomerative Cluster Analysis as a Trial Method Revealing Developmental Coordination Disorder (DCD) Subtypes
Background: There is increasing evidence that children with DCD have been classified into distinguishable ‘subtypes’ mainly based on perceptual-motor, fine and gross motor skills. Previous research efforts define and des...
Cutaneous Necrosis after Peripheral Venous Perfusion of Adrenaline
A 30 year old female patient was hospitalized for septic shock owing to peritonitis due to perforated viscus. The patient’s hemodynamic status was labile and a peripheral venous access line was established for the perfus...
Management of Pleural Effusion by Combining Talc Poudrage and Indwelling Pleural Catheter: A Retrospective Single Center Study
Objective: In 2013 we started to combine VATS poudrage with simultaneous insertion of an indwelling pleural catheter (IPC) for management of malignant pleural effusions (MPE) to achieve successful pleurodesis, avoid recu...
Being Principal Investigators on Pharma-initiated Clinical Trials: Have we Sold Ourselves Too Cheap?
The other day in clinic I was going through one of those good-clinical-practice (GCP) modules, as requested by one of the pharma companies in order for me to participate as an investigator in one of their clinical trial....
Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502
In November 2015 we began a feasibility study of salvage line chemotherapy with 5-fluorouracil and l-leucovorin given in an intravenous bolus once weekly followed by a 2-week rest period within a 8-week cycle in patients...